Tags

Type your tag names separated by a space and hit enter

Once daily intranasal fluticasone propionate (200 micrograms) reduces nasal symptoms and inflammation but also attenuates the increase in bronchial responsiveness during the pollen season in allergic rhinitis.
J Allergy Clin Immunol 1996; 98(2):274-82JA

Abstract

BACKGROUND

Fluticasone propionate aqueous nasal spray, a new topical corticosteroid, has been proved to be an effective treatment for seasonal allergic rhinitis.

OBJECTIVES

We studied the effect of fluticasone propionate on nasal symptoms, circulating eosinophils, and nasal inflammation in patients with seasonal allergic rhinitis after high-load pollen exposure. Moreover, we examined its efficacy in preventing the increase in bronchial responsiveness to methacholine (PD20) during the pollen season.

METHODS

We conducted a double-blind, placebo-controlled, parallel-group study in patients who had a history of allergic rhinitis in response to pollens of grass and Parietaria species and were living in northern Italy. After a run-in period of 2 weeks, 24 patients were treated with fluticasone propionate (200 micrograms, once daily), and 26 patients received matched placebo for 6 weeks, starting from the beginning of the pollen season. Assessment of efficacy was based on scores of daily nasal symptoms. Nasal lavage was performed at the end of the season, and differential cell count was expressed as percent of total cells. PD20 methacholine was measured at the beginning and end of the season and after the season had ended.

RESULTS

Fluticasone propionate significantly reduced nasal obstruction, itching, and rhinorrhea. Eosinophils in blood (p < 0.01) and nasal lavage (p < 0.001) were also reduced. Moreover, fluticasone significantly attenuated the decrease in mean PD20 methacholine (from 1.95 to 0.89 mg) compared with placebo (from 1.38 to 0.37 mg: p < 0.01). After the season, no difference in PD20 methacholine was found between treatment groups.

CONCLUSIONS

The results of this study indicate that fluticasone propionate is effective in decreasing nasal symptoms and eosinophil inflammation in patients with seasonal allergic rhinitis after high-load pollen exposure. Our results also demonstrate that treatment with fluticasone propionate partially prevents the increase in bronchial responsiveness provoked by the inhalation of seasonal pollens in allergic rhinitis.

Authors+Show Affiliations

Servizio di Fisiopatologia Respiratoria G. Campari, Sesto San Giovanni, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

8757203

Citation

Foresi, A, et al. "Once Daily Intranasal Fluticasone Propionate (200 Micrograms) Reduces Nasal Symptoms and Inflammation but Also Attenuates the Increase in Bronchial Responsiveness During the Pollen Season in Allergic Rhinitis." The Journal of Allergy and Clinical Immunology, vol. 98, no. 2, 1996, pp. 274-82.
Foresi A, Pelucchi A, Gherson G, et al. Once daily intranasal fluticasone propionate (200 micrograms) reduces nasal symptoms and inflammation but also attenuates the increase in bronchial responsiveness during the pollen season in allergic rhinitis. J Allergy Clin Immunol. 1996;98(2):274-82.
Foresi, A., Pelucchi, A., Gherson, G., Mastropasqua, B., Chiapparino, A., & Testi, R. (1996). Once daily intranasal fluticasone propionate (200 micrograms) reduces nasal symptoms and inflammation but also attenuates the increase in bronchial responsiveness during the pollen season in allergic rhinitis. The Journal of Allergy and Clinical Immunology, 98(2), pp. 274-82.
Foresi A, et al. Once Daily Intranasal Fluticasone Propionate (200 Micrograms) Reduces Nasal Symptoms and Inflammation but Also Attenuates the Increase in Bronchial Responsiveness During the Pollen Season in Allergic Rhinitis. J Allergy Clin Immunol. 1996;98(2):274-82. PubMed PMID: 8757203.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Once daily intranasal fluticasone propionate (200 micrograms) reduces nasal symptoms and inflammation but also attenuates the increase in bronchial responsiveness during the pollen season in allergic rhinitis. AU - Foresi,A, AU - Pelucchi,A, AU - Gherson,G, AU - Mastropasqua,B, AU - Chiapparino,A, AU - Testi,R, PY - 1996/8/1/pubmed PY - 1996/8/1/medline PY - 1996/8/1/entrez SP - 274 EP - 82 JF - The Journal of allergy and clinical immunology JO - J. Allergy Clin. Immunol. VL - 98 IS - 2 N2 - BACKGROUND: Fluticasone propionate aqueous nasal spray, a new topical corticosteroid, has been proved to be an effective treatment for seasonal allergic rhinitis. OBJECTIVES: We studied the effect of fluticasone propionate on nasal symptoms, circulating eosinophils, and nasal inflammation in patients with seasonal allergic rhinitis after high-load pollen exposure. Moreover, we examined its efficacy in preventing the increase in bronchial responsiveness to methacholine (PD20) during the pollen season. METHODS: We conducted a double-blind, placebo-controlled, parallel-group study in patients who had a history of allergic rhinitis in response to pollens of grass and Parietaria species and were living in northern Italy. After a run-in period of 2 weeks, 24 patients were treated with fluticasone propionate (200 micrograms, once daily), and 26 patients received matched placebo for 6 weeks, starting from the beginning of the pollen season. Assessment of efficacy was based on scores of daily nasal symptoms. Nasal lavage was performed at the end of the season, and differential cell count was expressed as percent of total cells. PD20 methacholine was measured at the beginning and end of the season and after the season had ended. RESULTS: Fluticasone propionate significantly reduced nasal obstruction, itching, and rhinorrhea. Eosinophils in blood (p < 0.01) and nasal lavage (p < 0.001) were also reduced. Moreover, fluticasone significantly attenuated the decrease in mean PD20 methacholine (from 1.95 to 0.89 mg) compared with placebo (from 1.38 to 0.37 mg: p < 0.01). After the season, no difference in PD20 methacholine was found between treatment groups. CONCLUSIONS: The results of this study indicate that fluticasone propionate is effective in decreasing nasal symptoms and eosinophil inflammation in patients with seasonal allergic rhinitis after high-load pollen exposure. Our results also demonstrate that treatment with fluticasone propionate partially prevents the increase in bronchial responsiveness provoked by the inhalation of seasonal pollens in allergic rhinitis. SN - 0091-6749 UR - https://www.unboundmedicine.com/medline/citation/8757203/Once_daily_intranasal_fluticasone_propionate__200_micrograms__reduces_nasal_symptoms_and_inflammation_but_also_attenuates_the_increase_in_bronchial_responsiveness_during_the_pollen_season_in_allergic_rhinitis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0091674996002114 DB - PRIME DP - Unbound Medicine ER -